NCT04042480: A Study of SGN-CD228A in Advanced Solid Tumors

NCT04042480
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received 1 or more prior lines of therapy for locally advanced or metastatic disease. Prior therapies must include a taxane; Hormone-receptor-positive subjects should have received CDK4/6 inhibitor therapy & at least 1 prior hormonally-directed therapy, unless contraindicated.
Exclusions: Patients with prior treatment of SGN228A or MMAE-containing agents
https://ClinicalTrials.gov/show/NCT04042480

Comments are closed.

Up ↑